Logo image of HYPR

HYPERFINE INC (HYPR) Stock Fundamental Analysis

NASDAQ:HYPR - Nasdaq - US44916K1060 - Common Stock - Currency: USD

1.075  +0.02 (+2.38%)

Fundamental Rating

3

Taking everything into account, HYPR scores 3 out of 10 in our fundamental rating. HYPR was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While HYPR has a great health rating, there are worries on its profitability. HYPR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HYPR has reported negative net income.
HYPR had a negative operating cash flow in the past year.
HYPR had negative earnings in each of the past 5 years.
HYPR had a negative operating cash flow in each of the past 5 years.
HYPR Yearly Net Income VS EBIT VS OCF VS FCFHYPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -75.48%, HYPR is not doing good in the industry: 74.33% of the companies in the same industry are doing better.
The Return On Equity of HYPR (-93.45%) is worse than 61.50% of its industry peers.
Industry RankSector Rank
ROA -75.48%
ROE -93.45%
ROIC N/A
ROA(3y)-56.89%
ROA(5y)-47.09%
ROE(3y)-64.86%
ROE(5y)-52.85%
ROIC(3y)N/A
ROIC(5y)N/A
HYPR Yearly ROA, ROE, ROICHYPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

HYPR's Gross Margin of 46.20% is in line compared to the rest of the industry. HYPR outperforms 40.11% of its industry peers.
HYPR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HYPR Yearly Profit, Operating, Gross MarginsHYPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

7

2. Health

2.1 Basic Checks

HYPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HYPR has more shares outstanding
HYPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HYPR Yearly Shares OutstandingHYPR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M
HYPR Yearly Total Debt VS Total AssetsHYPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

HYPR has an Altman-Z score of -4.75. This is a bad value and indicates that HYPR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.75, HYPR is not doing good in the industry: 70.59% of the companies in the same industry are doing better.
HYPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.75
ROIC/WACCN/A
WACC9.06%
HYPR Yearly LT Debt VS Equity VS FCFHYPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

HYPR has a Current Ratio of 6.07. This indicates that HYPR is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 6.07, HYPR belongs to the best of the industry, outperforming 82.35% of the companies in the same industry.
HYPR has a Quick Ratio of 5.48. This indicates that HYPR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of HYPR (5.48) is better than 82.89% of its industry peers.
Industry RankSector Rank
Current Ratio 6.07
Quick Ratio 5.48
HYPR Yearly Current Assets VS Current LiabilitesHYPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

HYPR shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.08%.
Looking at the last year, HYPR shows a small growth in Revenue. The Revenue has grown by 0.34% in the last year.
Measured over the past years, HYPR shows a very strong growth in Revenue. The Revenue has been growing by 105.01% on average per year.
EPS 1Y (TTM)5.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)0.34%
Revenue growth 3Y105.01%
Revenue growth 5YN/A
Sales Q2Q%-35.14%

3.2 Future

HYPR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.04% yearly.
HYPR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.76% yearly.
EPS Next Y15%
EPS Next 2Y11.13%
EPS Next 3Y9.36%
EPS Next 5Y8.04%
Revenue Next Year4.75%
Revenue Next 2Y16.37%
Revenue Next 3Y15.91%
Revenue Next 5Y16.76%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HYPR Yearly Revenue VS EstimatesHYPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 5M 10M 15M 20M 25M
HYPR Yearly EPS VS EstimatesHYPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HYPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HYPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HYPR Price Earnings VS Forward Price EarningsHYPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HYPR Per share dataHYPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.13%
EPS Next 3Y9.36%

More info and screens

0

5. Dividend

5.1 Amount

HYPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HYPERFINE INC

NASDAQ:HYPR (7/30/2025, 12:45:19 PM)

1.075

+0.02 (+2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-07 2025-08-07
Inst Owners13.91%
Inst Owner Change0%
Ins Owners1.84%
Ins Owner Change-0.36%
Market Cap83.68M
Analysts80
Price Target1.08 (0.47%)
Short Float %5.34%
Short Ratio1.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.24%
Min EPS beat(2)-16.81%
Max EPS beat(2)-1.67%
EPS beat(4)2
Avg EPS beat(4)-3.64%
Min EPS beat(4)-16.81%
Max EPS beat(4)1.96%
EPS beat(8)6
Avg EPS beat(8)3.64%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-24.86%
Min Revenue beat(2)-25.57%
Max Revenue beat(2)-24.15%
Revenue beat(4)2
Avg Revenue beat(4)-8.08%
Min Revenue beat(4)-25.57%
Max Revenue beat(4)9.07%
Revenue beat(8)4
Avg Revenue beat(8)-7.46%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-18.3%
EPS NQ rev (1m)-2.13%
EPS NQ rev (3m)-6.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.28%
Revenue NQ rev (1m)-1.8%
Revenue NQ rev (3m)-6.02%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.13
P/FCF N/A
P/OCF N/A
P/B 1.94
P/tB 1.94
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0.15
BVpS0.55
TBVpS0.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -75.48%
ROE -93.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.2%
FCFM N/A
ROA(3y)-56.89%
ROA(5y)-47.09%
ROE(3y)-64.86%
ROE(5y)-52.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 72.82%
Cap/Sales 6.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.07
Quick Ratio 5.48
Altman-Z -4.75
F-Score4
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)57.29%
Cap/Depr(5y)217.57%
Cap/Sales(3y)6.28%
Cap/Sales(5y)146.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y15%
EPS Next 2Y11.13%
EPS Next 3Y9.36%
EPS Next 5Y8.04%
Revenue 1Y (TTM)0.34%
Revenue growth 3Y105.01%
Revenue growth 5YN/A
Sales Q2Q%-35.14%
Revenue Next Year4.75%
Revenue Next 2Y16.37%
Revenue Next 3Y15.91%
Revenue Next 5Y16.76%
EBIT growth 1Y4.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.57%
EBIT Next 3Y11.71%
EBIT Next 5YN/A
FCF growth 1Y8.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.28%
OCF growth 3YN/A
OCF growth 5YN/A